Disheartening data from ResMed’s sleep apnea study gives Philips pause for thought
This article was originally published in Clinica
Executive Summary
Stocks in the respiratory disorders specialist ResMed have yet to recover after a thrashing last week following news that the company’s Phase IV trial to assess the benefits of sleep apnea therapy in heart failure patients had missed its primary endpoint.